drugset / Trial / NCT05227664
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Timeline
- Start
- 2022-03-23
- Primary completion
- 2026-12-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Background | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |